Defining and Interrupting Microenvironment-Driven Metabolic Activity in Brain Cancer


2025 Emerging Leader Award

Daniel Wahl, MD, PhD, University of Michigan Rogel Cancer Center

Daniel Wahl, MD, PhD

Glioblastoma (GBM) is an aggressive brain cancer with a high rate of recurrence, partly due to its ability to rewire its metabolism and adapt to harsh conditions. This project delves into the intricate metabolic interactions between GBM cells and their surrounding microenvironment. Dr. Wahl’s research has uncovered that GBM cells scavenge specific nutrients, called acetylated amino acids, from neighboring non-malignant cells. These scavenged nutrients alter the tumor’s metabolic pathways, promoting growth, DNA repair, and treatment resistance. By mapping these metabolic networks and identifying key players, this study aims to develop novel therapies that disrupt this metabolic crosstalk and improve outcomes for patients with GBM. 

Dr. Wahl is an Assistant Professor and physician-scientist in the Department of Radiation Oncology at the University of Michigan. His lab employs cutting-edge techniques, including stable isotope tracing and metabolomics, to study metabolic reprogramming in brain tumors. His group has a particular focus on purine metabolism and how the pathway can be inhibited in patients with brain tumors. This research builds upon Dr. Wahl’s expertise in cancer metabolism and is ultimately aimed at identifying novel therapies for patients with aggressive brain tumors. 

BACK TO OUR PORTFOLIO